Focetria

RSS
Expired

This medicine's authorisation has expired

influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)
MedicineHumanExpired
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Focetria (influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)) expired on 13 August 2015 following the decision of the marketing authorisation holder, Novartis Vaccines and Diagnostics S.r.l., not to apply for a renewal of the marketing authorisation. 

Novartis Vaccines and Diagnostics S.r.l. confirmed that it did not apply for renewal of the authorisation due to lack of demand for this product. 

Focetria was granted marketing authorisation in the European Union (EU) on 12 August 2010 for prophylaxis of influenza caused by A/H1N1v 2009 virus. The marketing authorisation was valid for a 5- year period. 

Novartis Vaccines and Diagnostics S.r.l. (now named Seqirus) is the marketing authorisation holder for another pandemic vaccine, Foclivia, which is authorised in the EU for pandemic preparedness. Seqirus will maintain the marketing authorisation for Foclivia. 

The European Public Assessment Report (EPAR) for Focetria is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (316.29 KB - PDF)

View

español (ES) (265.23 KB - PDF)

View

čeština (CS) (252.75 KB - PDF)

View

dansk (DA) (188.34 KB - PDF)

View

Deutsch (DE) (266.27 KB - PDF)

View

eesti keel (ET) (184.7 KB - PDF)

View

ελληνικά (EL) (260.74 KB - PDF)

View

français (FR) (267.92 KB - PDF)

View

italiano (IT) (249.62 KB - PDF)

View

latviešu valoda (LV) (307.5 KB - PDF)

View

lietuvių kalba (LT) (232.95 KB - PDF)

View

magyar (HU) (287.77 KB - PDF)

View

Malti (MT) (350.62 KB - PDF)

View

Nederlands (NL) (204.59 KB - PDF)

View

polski (PL) (251.96 KB - PDF)

View

português (PT) (265.45 KB - PDF)

View

română (RO) (293.74 KB - PDF)

View

slovenčina (SK) (250.89 KB - PDF)

View

slovenščina (SL) (297.16 KB - PDF)

View

Suomi (FI) (188.6 KB - PDF)

View

svenska (SV) (355.69 KB - PDF)

View

Product information

български (BG) (1.21 MB - PDF)

View

español (ES) (533.35 KB - PDF)

View

čeština (CS) (861.71 KB - PDF)

View

dansk (DA) (403.59 KB - PDF)

View

Deutsch (DE) (512.52 KB - PDF)

View

eesti keel (ET) (409.78 KB - PDF)

View

ελληνικά (EL) (1.02 MB - PDF)

View

français (FR) (540.01 KB - PDF)

View

hrvatski (HR) (545.62 KB - PDF)

View

íslenska (IS) (412.83 KB - PDF)

View

italiano (IT) (408.7 KB - PDF)

View

latviešu valoda (LV) (913.24 KB - PDF)

View

lietuvių kalba (LT) (576.67 KB - PDF)

View

magyar (HU) (681.56 KB - PDF)

View

Malti (MT) (854.26 KB - PDF)

View

Nederlands (NL) (503.28 KB - PDF)

View

norsk (NO) (508.91 KB - PDF)

View

polski (PL) (903.1 KB - PDF)

View

português (PT) (505.85 KB - PDF)

View

română (RO) (606.21 KB - PDF)

View

slovenčina (SK) (856.46 KB - PDF)

View

slovenščina (SL) (766.45 KB - PDF)

View

Suomi (FI) (412.85 KB - PDF)

View

svenska (SV) (1005.19 KB - PDF)

View
Latest procedure affecting product information: PSUV/0033
15/01/2015
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (224.93 KB - PDF)

View

español (ES) (148.48 KB - PDF)

View

čeština (CS) (228.9 KB - PDF)

View

dansk (DA) (208.82 KB - PDF)

View

Deutsch (DE) (148.51 KB - PDF)

View

eesti keel (ET) (136.7 KB - PDF)

View

ελληνικά (EL) (218.07 KB - PDF)

View

français (FR) (148.97 KB - PDF)

View

íslenska (IS) (142.61 KB - PDF)

View

italiano (IT) (144.37 KB - PDF)

View

latviešu valoda (LV) (249.13 KB - PDF)

View

lietuvių kalba (LT) (244.51 KB - PDF)

View

magyar (HU) (212.75 KB - PDF)

View

Malti (MT) (252.03 KB - PDF)

View

Nederlands (NL) (151.32 KB - PDF)

View

norsk (NO) (161.14 KB - PDF)

View

polski (PL) (253.29 KB - PDF)

View

português (PT) (151.29 KB - PDF)

View

română (RO) (242.96 KB - PDF)

View

slovenčina (SK) (250.17 KB - PDF)

View

slovenščina (SL) (209.18 KB - PDF)

View

Suomi (FI) (175.41 KB - PDF)

View

svenska (SV) (282.63 KB - PDF)

View

Product details

Name of medicine
Focetria
Active substance
Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/7/2009 (H1N1)-derived strain used NYMC X-181
International non-proprietary name (INN) or common name
influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
J07BB02

Pharmacotherapeutic group

Influenza vaccines

Therapeutic indication

Prophylaxis of influenza caused by A (H1N1v) 2009 virus.

Focetria should be used in accordance with official guidance.

Authorisation details

EMA product number
EMEA/H/C/000710
Marketing authorisation holder
Novartis Vaccines and Diagnostics S.r.l.

Via Fiorentina, 1
IT-53100 Siena
Italy

Marketing authorisation issued
02/05/2007
Expiry of marketing authorisation
13/08/2015
Revision
9

Assessment history

This page was last updated on

Share this page

OSZAR »